Published in Oncol Rep on September 01, 2005
Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis. Int J Colorectal Dis (2006) 1.32
Differences in telomerase activity between colon and rectal cancer. Can J Surg (2014) 0.92
Alterations of MEN1 and E-cadherin/β-catenin complex in sporadic pulmonary carcinoids. Int J Oncol (2012) 0.83
Review of the molecular profile and modern prognostic markers for gastric lymphoma: how do they affect clinical practice? Can J Surg (2012) 0.82
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol (2011) 8.66
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol (2007) 2.24
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J Clin Oncol (2007) 2.19
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst (2008) 1.92
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol (2004) 1.64
Variation of female and male lineages in sub-Saharan populations: the importance of sociocultural factors. Mol Biol Evol (2004) 1.63
Genetic studies of African populations: an overview on disease susceptibility and response to vaccines and therapeutics. Hum Genet (2008) 1.57
Performance at preoperative stair-climbing test is associated with prognosis after pulmonary resection in stage I non-small cell lung cancer. Ann Thorac Surg (2012) 1.49
Mitochondrial DNA from prehistoric canids highlights relationships between dogs and South-East European wolves. Mol Biol Evol (2005) 1.42
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer (2010) 1.40
The analysis of variation of mtDNA hypervariable region 1 suggests that Eastern and Western Pygmies diverged before the Bantu expansion. Am Nat (2004) 1.37
Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer (2012) 1.32
Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer (2009) 1.31
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials. Cancer Treat Rev (2013) 1.26
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options. Cancer Treat Rev (2010) 1.24
Subcellular localization of the BRCA1 gene product in mitotic cells. Genes Chromosomes Cancer (2002) 1.22
BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy. Cancer Res (2003) 1.22
J1-M267 Y lineage marks climate-driven pre-historical human displacements. Eur J Hum Genet (2009) 1.15
Role of maspin in cancer. Clin Transl Med (2013) 1.14
Pharmacogenetic profiling and clinical outcome of patients with advanced gastric cancer treated with palliative chemotherapy. J Clin Oncol (2006) 1.14
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer (2014) 1.11
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer (2008) 1.10
HER-2/neu amplification by fluorescence in situ hybridization in cytologic samples from distant metastatic sites of breast carcinoma. Cancer (2003) 1.10
Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol (2008) 1.10
Brief communication: mtDNA variation in North Cameroon: lack of Asian lineages and implications for back migration from Asia to sub-Saharan Africa. Am J Phys Anthropol (2005) 1.09
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother (2013) 1.08
Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence. BMC Microbiol (2011) 1.08
The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors. Gastroenterology (2009) 1.08
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer (2014) 1.08
Mitogen-activated protein kinases and NF-kappa B are involved in TNF-alpha responses to group B streptococci. J Immunol (2002) 1.07
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res (2010) 1.07
High neutrophil-to-lymphocyte ratio persistent during first-line chemotherapy predicts poor clinical outcome in patients with advanced urothelial cancer. Ann Surg Oncol (2014) 1.05
Pancreatic cancer: progress in cancer therapy. Crit Rev Oncol Hematol (2008) 1.04
Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene (2002) 1.04
FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemother Pharmacol (2012) 1.04
Autophagy in hematopoietic stem/progenitor cells exposed to heavy metals: Biological implications and toxicological relevance. Autophagy (2008) 1.04
Mutations of APC and MYH in unrelated Italian patients with adenomatous polyposis coli. Hum Mutat (2005) 1.03
The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management. PLoS One (2012) 1.03
Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Clin Cancer Res (2004) 1.02
Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip Rev Syst Biol Med (2011) 1.02
Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report. Br J Haematol (2004) 1.01
Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor. Int J Cancer (2013) 1.01
Progress of molecular targeted therapies for advanced renal cell carcinoma. Biomed Res Int (2013) 1.00
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther (2010) 1.00
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastases. Int J Radiat Oncol Biol Phys (2006) 1.00
Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. Anticancer Res (2013) 1.00
Concentration of circulating endothelial progenitor cells (EPC) in normal pregnancy and in pregnant women with diabetes and hypertension. Am J Obstet Gynecol (2007) 0.98
HDACs class II-selective inhibition alters nuclear receptor-dependent differentiation. J Mol Endocrinol (2010) 0.98
The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. Expert Opin Investig Drugs (2014) 0.98
The insulin receptor substrate 1 (IRS1) in intestinal epithelial differentiation and in colorectal cancer. PLoS One (2012) 0.98
The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab. Oncologist (2011) 0.97
Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. Cancer Treat Rev (2004) 0.97
Prostaglandin E2 induces interleukin-8 gene transcription by activating C/EBP homologous protein in human T lymphocytes. J Biol Chem (2005) 0.96
Cancer in the Sudan: an overview of the current status of knowledge on tumor patterns and risk factors. Sci Total Environ (2010) 0.96
ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. J Cell Physiol (2006) 0.96
Identification of a novel mutation affecting domain V of the 23S rRNA gene in Helicobacter pylori. Helicobacter (2004) 0.95
Immunocytochemical evaluation of HER-2/neu on fine-needle aspirates from primary breast carcinomas. Diagn Cytopathol (2003) 0.95
Impact of DNA methyltransferases on the epigenetic regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in malignant melanoma. Biochem Biophys Res Commun (2013) 0.94
5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics (2011) 0.93
Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation. Crit Rev Oncol Hematol (2013) 0.93
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis (2012) 0.92
The effect of two different protocols of potassium haemodiafiltration on QT dispersion. Nephrol Dial Transplant (2005) 0.92
BRCA1 and BRCA2 status in a Central Sudanese series of breast cancer patients: interactions with genetic, ethnic and reproductive factors. Breast Cancer Res Treat (2007) 0.91
MSX1 and TGF-beta3 are novel target genes functionally regulated by FOXE1. Hum Mol Genet (2010) 0.91
Role of osteopontin in breast cancer patients. Tumori (2009) 0.91
Pseudomonas aeruginosa induces interleukin-8 (IL-8) gene expression in human conjunctiva through the recruitment of both RelA and CCAAT/enhancer-binding protein beta to the IL-8 promoter. J Biol Chem (2008) 0.91
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab. J Transl Med (2012) 0.91
A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer? Eur J Cancer (2004) 0.90
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study. Oncology (2007) 0.90
Chemotherapy for advanced gastric cancer: across the years for a standard of care. Expert Opin Pharmacother (2007) 0.90
Association of thymidylate synthase polymorphisms with gastric cancer susceptibility. Int J Cancer (2004) 0.90
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials. Int J Cancer (2013) 0.89
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. Expert Opin Biol Ther (2014) 0.89
Essential role of Gli proteins in glioblastoma multiforme. Curr Protein Pept Sci (2013) 0.89
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer (2008) 0.89
Bioinformatic pipelines in Python with Leaf. BMC Bioinformatics (2013) 0.89
Pathogenic and Diagnostic Potential of BLCA-1 and BLCA-4 Nuclear Proteins in Urothelial Cell Carcinoma of Human Bladder. Adv Urol (2012) 0.89
A novel T608R missense mutation in insulin receptor substrate-1 identified in a subject with type 2 diabetes impairs metabolic insulin signaling. J Clin Endocrinol Metab (2003) 0.89
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors. Ann Surg Oncol (2014) 0.89
Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. PLoS One (2013) 0.88
Functional characterization of two secreted SEL1L isoforms capable of exporting unassembled substrate. J Biol Chem (2009) 0.88
Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. PLoS One (2013) 0.88
State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit Rev Oncol Hematol (2013) 0.87